Eleanor Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Outpatient addiction and mental health treatment platform, Boston MA, raised $50M+. Value-based care model integrating SUD treatment with mental health support.
About
Eleanor Health is a Boston, Massachusetts-based behavioral health company founded in 2019 that provides value-based outpatient treatment for substance use disorder (SUD) combined with mental health care. The company has raised over $50 million and operates in multiple states through a hybrid model that combines telehealth with community-based care hubs staffed by multidisciplinary care teams. Eleanor Health treats addiction to opioids, alcohol, and other substances alongside co-occurring mental health conditions such as depression, anxiety, and PTSD.\n\nEleanor Health's care model is built around value-based contracts with Medicaid managed care organizations and commercial health plans, aligning the company's financial incentives with patient outcomes rather than visit volume. Care teams include addiction medicine specialists, therapists, care coordinators, and community health workers who support patients through recovery with a whole-person approach. The platform integrates medication-assisted treatment (MAT), individual and group therapy, and social needs navigation into a coordinated care program.\n\nThe company focuses on serving Medicaid populations with high rates of co-occurring substance use and mental health conditions, a population that historically experiences fragmented care across separate addiction and mental health service systems. Eleanor Health's integrated model is designed to reduce emergency department utilization, hospitalizations, and crisis episodes among high-need members. The company has partnered with several state Medicaid programs and commercial payers to expand access to its model across the Southeast and other regions.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.